Breaking News Instant updates and real-time market news.

AMRN

Amarin

$15.39

-4.44 (-22.39%)

07:43
11/14/18
11/14
07:43
11/14/18
07:43

Amarin upgraded to Buy from Neutral at Citi

AMRN Amarin
$15.39

-4.44 (-22.39%)

11/08/18
11/08/18
INITIATION

On The Fly: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Stanley Black & Decker (SWK) initiated with a Hold at Deutsche Bank. 2. Comcast (CMCSA) resumed with an Overweight at Morgan Stanley while Amarin (AMRN) and Immunomedics (IMMU) were assumed with a Buy at the firm. 3. Broadcom (AVGO) resumed with a Buy at Deutsche Bank and reinstated with an Overweight at JPMorgan. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/12/18
HCWC
11/12/18
NO CHANGE
Target $51
HCWC
Buy
Amarin price target raised to $51 from $31 at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein raised his price target for Amarin to $51 from $31 and reiterates a Buy rating on the shares. The stock in premarket trading is down 3%, or 55c, to $20.50. The detailed data presentation of the Reduce-IT trial of Vascepa at this year's American Heart Association conference in conjunction with the publication in the New English Journal of Medicine provided much anticipated color on Vascepa's clinical benefits and commercial potential, Fein tells investors in a research note. He believes that beyond the topline of 25% reduction of MACE score, the "robustness of the data is highlighted by the consistency across pre-specified analyses." The trial data may be viewed as "unprecedented" and "paradigm-changing" in the context of minimal or modest benefits historically achieved by various therapies on top of statins, says the analyst.
11/13/18
MAXM
11/13/18
NO CHANGE
Target $5
MAXM
Buy
Matinas BioPharma price target raised to $5 from $2 at Maxim
Maxim analyst Jason McCarthy raised his price target on Matinas BioPharma (MTNB) to $5 and kept his Buy rating after its Q3 results. The analyst adds that he is also factoring in the impact of MAT9001 after the outcome of data evaluating Amarin's (AMRN) Vascepa + Statin, and the company's decision to move MAT9001 forward for hypertriglyceridemia.
11/13/18
CANT
11/13/18
NO CHANGE
Target $35
CANT
Overweight
Physicians not concerned about label for Vascepa, says Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen said based on her discussions with doctors in attendance at the AHA meeting, she believes the physician community remains "very receptive" to the REDUCE-IT data and noted that "no one" she spoke with seemed concerned about label limitations for Vascepa. Chen also noted that an audience poll during one Continuing Medical Education program showed that nearly all of the physicians in the audience plan to prescribe EPA 4g/day for patients with triglycerides between 200-500 mg/dL. Chen maintains an Overweight rating and $35 price target on Amarin shares.

TODAY'S FREE FLY STORIES

SSNLF

Samsung

$0.00

(0.00%)

05:58
04/22/19
04/22
05:58
04/22/19
05:58
Hot Stocks
Samsung postpones Galaxy Fold launch events in Hong Kong, Engadget's Lai says »

Richard Lai, Engadget…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BCRX

BioCryst

$7.92

0.22 (2.86%)

05:48
04/22/19
04/22
05:48
04/22/19
05:48
Recommendations
BioCryst analyst commentary at Piper Jaffray »

Piper sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAL

American Airlines

$34.37

-0.01 (-0.03%)

, BA

Boeing

$380.02

2.48 (0.66%)

05:24
04/22/19
04/22
05:24
04/22/19
05:24
Recommendations
American Airlines, Boeing analyst commentary  »

American Airlines shares…

AAL

American Airlines

$34.37

-0.01 (-0.03%)

BA

Boeing

$380.02

2.48 (0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 26

    Apr

  • 29

    Apr

  • 29

    May

  • 05

    Jun

  • 12

    Jun

ATVI

Activision Blizzard

$45.29

0.31 (0.69%)

, EA

Electronic Arts

$93.13

1.19 (1.29%)

05:19
04/22/19
04/22
05:19
04/22/19
05:19
Recommendations
Activision Blizzard, Electronic Arts, Take-Two analyst commentary at Piper Jaffray »

March NPD video game…

ATVI

Activision Blizzard

$45.29

0.31 (0.69%)

EA

Electronic Arts

$93.13

1.19 (1.29%)

TTWO

Take-Two

$90.73

0.97 (1.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 07

    May

  • 13

    May

  • 29

    May

  • 13

    Nov

ATVI

Activision Blizzard

$45.29

0.31 (0.69%)

, ZNGA

Zynga

$5.43

0.175 (3.33%)

05:16
04/22/19
04/22
05:16
04/22/19
05:16
Recommendations
Activision Blizzard, Zynga, Glu Mobile, Electronic Arts, Take-Two analyst commentary  »

Activision, Zynga Q1…

ATVI

Activision Blizzard

$45.29

0.31 (0.69%)

ZNGA

Zynga

$5.43

0.175 (3.33%)

GLUU

Glu Mobile

$10.63

0.195 (1.87%)

EA

Electronic Arts

$93.13

1.19 (1.29%)

TTWO

Take-Two

$90.73

0.97 (1.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 02

    May

  • 06

    May

  • 07

    May

  • 07

    May

  • 13

    May

  • 15

    May

  • 16

    May

  • 29

    May

  • 13

    Nov

RUSMF

Russel Metals

$0.00

(0.00%)

05:09
04/22/19
04/22
05:09
04/22/19
05:09
Initiation
Russel Metals initiated  »

Russel Metals initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FNLPF

Fresnillo

$0.00

(0.00%)

05:08
04/22/19
04/22
05:08
04/22/19
05:08
Downgrade
Fresnillo rating change  »

Fresnillo downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLRN

Acceleron

$39.65

-0.8 (-1.98%)

05:06
04/22/19
04/22
05:06
04/22/19
05:06
Upgrade
Acceleron rating change at Oppenheimer »

Acceleron assumed with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

  • 31

    May

EAF

GrafTech

$13.93

-0.045 (-0.32%)

05:00
04/22/19
04/22
05:00
04/22/19
05:00
Downgrade
GrafTech rating change at Citi »

GrafTech downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Apr

  • 01

    May

VIAV

Viavi

$12.69

-0.135 (-1.05%)

04:56
04/22/19
04/22
04:56
04/22/19
04:56
Upgrade
Viavi rating change  »

Viavi upgraded to Neutral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

NBIX

Neurocrine

$78.39

-2.78 (-3.42%)

04:55
04/22/19
04/22
04:55
04/22/19
04:55
Upgrade
Neurocrine rating change at JPMorgan »

Neurocrine upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Apr

  • 04

    May

  • 22

    May

MSM

MSC Industrial

$83.37

-0.44 (-0.52%)

04:55
04/22/19
04/22
04:55
04/22/19
04:55
Conference/Events
MSC Industrial management to meet with William Blair »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 23

    Apr

  • 24

    Apr

  • 05

    Jun

  • 13

    Nov

SMAR

Smartsheet

$40.20

0.495 (1.25%)

04:55
04/22/19
04/22
04:55
04/22/19
04:55
Conference/Events
Smartsheet management to meet with Stephens »

Field Trip to visit with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 05

    Jun

04:55
04/22/19
04/22
04:55
04/22/19
04:55
General news
Breaking General news story  »

3-Month Bill Auction to…

EIDX

Eidos Therapeutics

$23.57

0.14 (0.60%)

04:55
04/22/19
04/22
04:55
04/22/19
04:55
Conference/Events
Eidos Therapeutics management to meet with Roth Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 23

    Apr

04:55
04/22/19
04/22
04:55
04/22/19
04:55
General news
Existing Home Sales to be reported at 10:00 »

March Existing Home Sales…

04:55
04/22/19
04/22
04:55
04/22/19
04:55
General news
Breaking General news story  »

6-Month Bill Auction to…

AKBA

Akebia

$6.71

-0.22 (-3.17%)

04:55
04/22/19
04/22
04:55
04/22/19
04:55
Conference/Events
Akebia management to meet with Piper Jaffray »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 06

    May

KELTF

Kelt Exploration

$0.00

(0.00%)

04:55
04/22/19
04/22
04:55
04/22/19
04:55
Conference/Events
Kelt Exploration management to meet with TD Securities »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 23

    Apr

04:55
04/22/19
04/22
04:55
04/22/19
04:55
Conference/Events
UBS technology analyst to hold an analyst/industry conference call »

Technology Analyst…

FRCOY

Fast Retailing

$0.00

(0.00%)

04:53
04/22/19
04/22
04:53
04/22/19
04:53
Downgrade
Fast Retailing rating change  »

Fast Retailing downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LRCX

Lam Research

$194.75

-1.57 (-0.80%)

04:51
04/22/19
04/22
04:51
04/22/19
04:51
Upgrade
Lam Research rating change at B. Riley FBR »

Lam Research upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 29

    May

AGEN

Agenus

$2.52

-0.025 (-0.98%)

04:50
04/22/19
04/22
04:50
04/22/19
04:50
Initiation
Agenus initiated at B. Riley FBR »

Agenus initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DHI

D.R. Horton

$46.42

0.65 (1.42%)

04:48
04/22/19
04/22
04:48
04/22/19
04:48
Downgrade
D.R. Horton rating change  »

D.R. Horton downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

AMZN

Amazon.com

$1,862.11

-2.52 (-0.14%)

, KR

Kroger

$25.78

0.22 (0.86%)

19:17
04/21/19
04/21
19:17
04/21/19
19:17
Hot Stocks
Fly Intel: Top five weekend stock stories »

Catch up on the…

AMZN

Amazon.com

$1,862.11

-2.52 (-0.14%)

KR

Kroger

$25.78

0.22 (0.86%)

WMT

Walmart

$103.15

0.02 (0.02%)

TGT

Target

$83.23

0.51 (0.62%)

TSLA

Tesla

$273.25

2.13 (0.79%)

UNH

UnitedHealth

$221.74

4.93 (2.27%)

ANTM

Anthem

$239.63

3.38 (1.43%)

CI

Cigna

$148.95

3.46 (2.38%)

HUM

Humana

$240.65

7.645 (3.28%)

CVS

CVS Health

$52.62

0.08 (0.15%)

T

AT&T

$32.04

0.09 (0.28%)

SPOT

Spotify

$139.53

1.88 (1.37%)

SAM

Boston Beer

$266.90

0.89 (0.33%)

PINS

Pinterest

$24.46

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 25

    Apr

  • 26

    Apr

  • 29

    Apr

  • 30

    Apr

  • 01

    May

  • 01

    May

  • 02

    May

  • 06

    May

  • 06

    May

  • 07

    May

  • 07

    May

  • 10

    May

  • 15

    May

  • 16

    May

  • 16

    May

  • 16

    May

  • 18

    May

  • 19

    May

  • 20

    May

  • 22

    May

  • 23

    May

  • 29

    May

  • 03

    Jun

  • 05

    Jun

  • 07

    Jun

  • 18

    Jun

  • 13

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.